Introduction
Hypoxic regions are common in solid tumours such as breast cancer as well as in metastases. 1, 2 Hypoxic areas arise because tumour cells grow rapidly and outpace the formation of new blood vessels. 3 Even mild anaemia in breast cancer patients is linked to the formation of hypoxic tumour regions. 4 One of the key factors adapting tumour cells to hypoxic conditions is HIF-1α (hypoxia inducible factor 1α). 5 At normal oxygen tension, HIF-1α is continuously degraded through the proteasomal system via binding to the von Hippel-Lindow (VHL)-protein, but during hypoxia VHL can no longer bind to HIF-1α causing an accumulation of HIF-1α. 6 HIF-1α is active as a transcription factor in a heterodimeric complex together with HIF-1β or ARNT and binds to DNA sequences called HRE´s (hypoxia responsive elements). 7 HIF-1α has the potential to activate a number of genes known to be involved in tumour progression, invasion and neoangiogenesis, for example VEGF, glucose transporters, carbonic anhydrases, Met receptor, insulin growth factor-1, UPAR, and transforming growth factor-α. 8 HIF-1α expression is not only restricted to hypoxic cells, but is also upregulated by growth factors, such as insulin growth factor 1, insulin, 9 heregulin 10 and oncogenic mutations in RAS, 11 p53, 12 PTEN, 13 SCR, ERBB2 14 or VHL. 15, 16 In general, hypoxia negatively influences tumour prognostic features and causes resistance to many standard therapies and promotes a more malignant phenotype. 17 HIF-1α expression is not detected in normal breast tissue or hyperplastic lesions but is present in well-differentiated ductal carcinoma in situ and in all more malignant forms of breast cancer. 18 In poorly differentiated ductal carcinoma in situ, HIF-1α expression has been correlated to loss of estrogen receptor (ER) expression as well as a more undifferentiated phenotype. 19 From studies of breast cancer cell lines it appears that hypoxia also correlates to loss of ER expression [20] [21] [22] [23] and that this may induce tamoxifen resistant growth. 24 Hormone independent growth is frequently caused by abnormalities in growth factor signaling pathways such as EGFR, HER2, MAPK-singalling via ERK1/2, or IGFR via PI3K, 25 all of which may be influenced by HIF-1α. HIF-1α has also been implicated as an independent prognostic marker in both lymph node negative 26 as well as lymph node positive breast cancers. 27, 28 Also, high histological grade, ER and PR (progesterone receptor) negativity and the presence of necrotic regions have been linked to the presence of HIF-1α, 29 but the relation between histological grade, ER status and HIF-1α expression differs between reports. 14, 26, 27 This difference could potentially be explained by the fact that the role of HIF-1α as a prognostic marker was investigated in small cohorts of pre and postmenopausal patients with both early and advanced breast cancer, receiving different forms of treatment.
We therefore investigated the prognostic information of HIF-1α expression in tumours from patients participating in a randomised trial of two years adjuvant tamoxifen versus no The study has been approved by the ethical committees at Linköping and Lund Universities. (3) or negative (0-2) cytoplasmic staining. 31 By using the tissue microarray approach, staining variation between samples were minimised and positive samples could be used as supplements for internal controls. Her2 gene amplification was determined using FISH (fluorescent in situ hybridisation) according to standard protocols (Ventana Medi-manufacturer's Systems Ind.,AZ, USA) and described elsewhere. 31 
Statistics
Differences in distribution between HIF-1α negative/low and HIF-1α high tumours, regarding clinical data and tumour characteristics were evaluated by the χ 2 test. Kaplan-Meier's plot and log rank test were used for illustrating and calculating RFS. The Cox multivariate proportional hazards model was fitted to explore the effects on RFS of HIF-1α, tumour size, Her2, lymph node status, NHG, Ki-67 in the untreated patients; the analysis was also preformed after NHG 3 exclusion. All calculations were performed in SPSS version 11.0 (SPSS Inc, Chicago, IL, USA).
Results

Distribution of HIF-1α
Immunohistochemical tumor specific HIF-1α expression could be evaluated in 377 (67%) of the tumours (table 1) 
HIF-1α and tamoxifen treatment response
In the treated patient cohort, only patients with ER-positive tumours responded to tamoxifen treatment 30 and this subgroup was therefore selected for further studies of a potential link between HIF-1α expression and tamoxifen response. By comparing tamoxifen treated patients with untreated patients within subgroups of ER-positive tumours defined by HIF-1α expression, the tamoxifen response in relation to HIF-1α could be defined. As illustrated in 
HIF-1α and survival
In the entire cohort of patients (n=377) there was a significantly worse RFS for patients with HIF-1α high tumour (p=0.048) compared to negative or low expression ( figure 3A) . There was further a trend towards a worse overall survival for patients with HIF-1α high tumours (p=0.12) (figure 3B), as well as significant difference in breast cancer specific survival (p=0.028) ( figure 3C ). We next restricted the recurrence free survival analysis to the 288 untreated patients in order to investigate pure prognostic information in relation to HIF-1α staining. Interestingly, there was no significant difference in RFS in relation to HIF-1α in the untreated patients even though there was a non-significant trend towards an impaired RFS for patients with HIF-1α high tumours ( figure 4A ). This trend was slightly more apparent in the subgroup analysis including only ductal breast cancers ( figure 4B ). In the tamoxifen treated cohort, HIF-1α showed a similar trend towards worse RFS (p=0.14). Earlier reports have observed independent prognostic values for HIF-1α in lymph node-negative breast cancer 26 as well as in lymph node-positive breast cancer patients, 27 and we therefore analysed the subgroups of lymph node-negative (n=50) and lymph node-positive (n=145) untreated control cases separately ( figure 4 C,D) . There was no significant association to RFS in the subgroup of lymph node-negative patients but there was a significant association between a shorter RFS and HIF-1α expression in the lymph node-positive subgroup. To further investigate the prognostic information of HIF-1α we analyzed the subgroups of NHG 1/2 tumours versus NHG 3 tumours. In NHG 1/2 tumours HIF-1α high expression was significantly linked to a shorter RFS (figure 4 E) whereas there was no significant association between HIF-1α and RFS in the NHG 3 tumours (figure 4 F). In the treated cohort, there were no significant associations between HIF-1α and RFS in either lymph node-negative (p=0.088) or lymph node-positive patients (p=0.46) or NHG1/2 tumours (p=0.70) or in NHG 3 tumours (p=0.24). Table 4 shows the results of multivariate analysis of RFS in the untreated cohort of patients.
When including all untreated patients, HIF-1α was not an independent prognostic factor in contrast to node status and NHG. However, when taking the above-presented results into account and excluding the NHG 3 tumours from the multivariate analysis, only HIF-1α remained an independent prognostic marker for RFS (table 5) .
Discussion
The aim of this study was to investigate the role of HIF-1α as a prognostic marker in stage II premenopausal breast cancer patients in relation to RFS using a randomised study cohort. The prognostic impact of HIF-1α in breast cancer has neither been explored in an untreated patient cohort and neither with regards to tamoxifen response in a randomised treatment trial cohort.
In the whole material, 24% of the tumours showed nuclear HIF-1α staining, which is in concordance with other articles even if the patient cohorts differ between the reported studies. 27, 28, 32 ER down-regulation in breast cancer cell lines as well as in primary breast cancer has been linked to HIF-1α induction. 14, 19, 20, 26 In contrast, ER positivity has also been reported to be associated with HIF-1α expression 18 whereas others have not observed any significant link between HIF-1α and ER expression. 27, 28 Decreased ER expression and its downstream target PR in tumour cells surrounding necrotic zones are nevertheless obvious 19, 22, 29 and despite some inconsistencies between studies, there seems to be an inverse link between HIF-1α expression and ER in both experimental models as well as in in vivo tumors. The data presented in this study further supports a link between HIF-1α and the presence of ER in breast cancer but surprisingly not to the tamoxifen response as further deliberated below.
HIF-1α is considered to support tumour growth and the significant association between tumour size and HIF-1α observed in this study fits well with this theory. For some reason this correlation appears to be lost when analysing T1, T2 and T3 tumours together 14 or T1, T2 versus T3, T4. 28 Our data suggest that HIF-1α and tumour size is correlated in tumours up to 5 cm in size, but in larger tumours other factors might be more important in regulating tumour size or growth. Further, HIF-1α was associated with proliferation in this study indicating the presence of HIF-1α in actively proliferating cells, which is in line with other publications. 18, 26 Proliferating cells are under the control of proteins in the cell cycle and HIF-1α appears to be positively associated to proteins involved in S/G 2 -phase such as cyclin E and cyclin A2, but negatively associated to cyclin D1, which, mainly functions in early G 1 -phase. This is in concordance with earlier published data 33 but apart from the association to the cell cycle this could also indicate that HIF-1α expression is correlated to a certain type of breast cancer with proliferative features and frequent overexpression of cyclin E. 34, 35 HIF-1α has not previously been explored in relation to treatment prediction in a randomised treatment trial, but one breast cancer cell line study has demonstrated that hypoxia induces tamoxifen resistant growth. 24 In our study we could not confirm this link between hypoxia and tamoxifen response and both HIF-1α low and high tumour appeared to respond to tamoxifen treatment. Since there is a negative association between ER and HIF-1α expression, the amount of ER-positive and HIF-1α high tumours was rather small in this study, which might have affected the results, but despite few tumours there was a significant tamoxifen effect in the subgroup of HIF-1α high tumours, clearly suggesting that these tumours indeed have a functional tamoxifen response. Nevertheless, cell line studies indicate that ER positive breast cell lines downregulate the ER under hypoxic conditions, which is in contrast to the existence of tumours with a high ER and HIF-1α expression as observed in this study. 19 It is possible that the tumours with a high HIF-1α expression and ER-positivity represent a subgroup of tumours where HIF-1α expression is under the control of growth factor signaling and perhaps not hypoxia, which could affect the results concerning ER-content and tamoxifen response.
HIF-1α has been correlated to VEGF-expression in progressive breast cancer stages and in a subgroup of lymph node-and ER-negative cancer. 18, 26, 33 The relation of VEGF to HIF-1α expression has not been investigated in lymph node positive patients. Surprisingly, we did not observe any association between HIF-1α and VEGF-A expression in the whole cohort nor in the ER positive or negative cohort, nor in lymph node positive or negative disease (data not shown). Since hormonal stimulation (estrogen) regulate VEGF secretion in breast cancer 36, 37 we speculate that this might influence the outcome of correlation analysis in the present tumour material. EGF signaling has also been shown to regulate the VEGF-levels, 38 potentially further influencing the analysis. Recently it was shown that there is an inverse balance between the amount of VEGFR1 and VEGF levels in breast cancer, and the balance is partly dependent on hormonal stimulation. 39 In general, our outcome data including breast cancer recurrence, overall survival and breast cancer specific survival strengthen and clarify the findings of others, 14, [26] [27] [28] suggesting that HIF-1α is linked to aggressive tumour features and a bad prognosis for breast cancer patients.
The patient group where this correlation is of prognostic value is nevertheless a matter of debate and different reports show different results. In lymph node-negative patients it has previously been shown that HIF-1α correlated to a worse prognosis whereas in the lymph node-positive cohort there were no such association. 26 Others have shown that HIF-1α was indeed prognostic in a lymph node-positive cohort 27 of T1 and T2 tumours. 28 HIF-1α expression has also been observed to increase with an increasing occurrence of lymph node metastasis, 14 which is in direct disagreement with our data where HIF-1α expression is inversely correlated to lymph node status. In an attempt to clarify the prognostic information in HIF-1α expression and lymph node status we used the untreated patient cohort where interference of different treatment regimes on survival can be minimised. We found that HIF-1α was not associated with outcome (RFS) in lymph nodenegative cancer in contrast to lymph node-positive cancer. In the entire cohort of lymph nodenegative tumours, HIF-1α showed a trend (p=0.12) towards a shorter survival that possibly could be an indirect result of treatment since this trend completely disappeared in the control cohort. Speculatively, HIF-1α high tumours do not seem to commonly metastasize, but if they do, HIF-1α expression indeed seem to be linked to aggressive features and a bad prognosis.
In this study we observed a positive correlation between HIF-1α and NHG, which is supported by the fact that a high histological grade and the presence of necrotic regions in breast tumours are closely associated. 29 Further, this association was also observed in a study cohort of 153 stage I/II invasive breast cancers 26 but not in studies where only lymph nodepositive patients were included. 27, 28 In the present cohort, the correlation between NHG and HIF-1α expression persisted, also when analysing the lymph node-positive control cohort only Table 2 Clinical data and tumour characteristics according to HIF-1α in two groups. Table 4 Recurrence free survival with Cox-multivariate analysis for untreated patients. 
